Seasonal and age-related variations impacting HPV vaccination uptake in Romania

نویسندگان

  • Oana Streinu-Cercel
  • Anca Streinu-Cercel
  • Alexandru Rafila
  • Adrian Pană
  • Adriana Pistol
  • Mihai Săndulescu
  • Adrian Streinu-Cercel
چکیده

Results In the studied time span 80,509 HPV vaccine doses were administered in Romania, 46% (37,359) of these representing the third and final dose of the vaccination regimen. By the end of June 2013, 38,281 women of all ages had completed the full 3-dose HPV vaccination regimen. The studied time span appears to show a biphasic evolution of the vaccination schedule: between June 2010 and August 2011, absolute numbers were constantly above 1,500 doses per month, while after August 2011 there was an important decrease, with the total number of shots per months constantly below 1,000 but above 150. The months with the lowest numbers reported were April (2,787), June (2,196) and July (1,649) 2011 in the first time span and September (250), October (245) 2011, September 2012 (186), February (227) and March (205) 2013 for the second time span. The number of girls undergoing vaccination during June-December 2010 was higher in the lower age groups, with 10,456 girls in the 12-14 years old age group, 13,135 (15-19 years old), 15,723 (20-24 years old), 10,785 (age 24 and over). After 2011, the proportions changed, with the largest numbers of vaccines being administered at increasingly higher ages: 1,671 (12-14 years old), 4,737 (15-19 years old), 8,152 (20-24 years old), 9,800 (age 24 and over) during 2011; 319 (12-14 years old), 598 (15-19 years old), 1,585 (20-24 years old), 1,821 (age 24 and over) during 2012 and 120 (12-14 years old), 215 (15-19 years old), 518 (20-24 years old), 874 (age 24 and over) during JanuaryJune 2013.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Mass media coverage of HPV vaccination in Romania: a content analysis.

Romania has the highest cervical cancer burden in Europe. Despite the implementation of two human papillomavirus (HPV) vaccination programmes, the uptake remained extremely low and the programmes were discontinued. Given that media are a common source of information for the public and may influence vaccination decisions, this article sought to explore the content and quality of HPV vaccine medi...

متن کامل

Modeling the consequences of regional heterogeneity in human papillomavirus (HPV) vaccination uptake on transmission in Switzerland.

BACKGROUND Completed human papillomavirus (HPV) vaccination by age 16 years among women in Switzerland ranges from 17 to 75% across 26 cantons. The consequences of regional heterogeneity in vaccination coverage on transmission and prevalence of HPV-16 are unclear. METHODS We developed a deterministic, population-based model that describes HPV-16 transmission among young adults within and betw...

متن کامل

MOJ Bioequivalence & Bioavailability Development and Validation of ‘Educational Pamphlet’ in Prevention of Human Papilloma Virus (HPV) Infection among Age Eligible Adults for HPV Vaccination in Kedah State, Malaysia

Human papillomavirus (HPV) is one of the most common sexually transmitted infections (STI), and cumulative prevalence rates have been reported up to 82% in sexually active adolescent and young adults in the United States [1], whereas, genital warts are common, in Malaysia but its prevalence has not been determined yet. A commendable knowledge of Human Papilloma Virus (HPV) infection is essentia...

متن کامل

Cost-Effectiveness Evaluation of Quadrivalent Human Papilloma Virus Vaccine for HPV-Related Disease in Iran

Human Papilloma Virus (HPV) vaccine recently has been added to the Iran Drug List, decision makers need information beyond that available from RCTs to recommend funding for this vaccination program to add it to the National Immunization program in Iran. Modeling and economic studies have addressed some of those information needs in foreign countries. In order to determine the long term benefit ...

متن کامل

Cost-Effectiveness Evaluation of Quadrivalent Human Papilloma Virus Vaccine for HPV-Related Disease in Iran

Human Papilloma Virus (HPV) vaccine recently has been added to the Iran Drug List, decision makers need information beyond that available from RCTs to recommend funding for this vaccination program to add it to the National Immunization program in Iran. Modeling and economic studies have addressed some of those information needs in foreign countries. In order to determine the long term benefit ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 13  شماره 

صفحات  -

تاریخ انتشار 2013